CVS Health (NYSE:CVS) has been given a $100.00 price target by research analysts at Morgan Stanley in a report released on Wednesday, November 7th, The Fly reports. The brokerage presently has a “buy” rating on the pharmacy operator’s stock. Morgan Stanley’s price objective indicates a potential upside of 26.06% from the stock’s current price.
Other equities analysts have also issued reports about the company. Royal Bank of Canada set a $99.00 target price on CVS Health and gave the company a “buy” rating in a research note on Tuesday, October 23rd. Bank of America upped their target price on CVS Health from $86.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, September 17th. ValuEngine upgraded CVS Health from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 28th. Tigress Financial reiterated a “buy” rating on shares of CVS Health in a research note on Friday, October 26th. Finally, Wolfe Research assumed coverage on CVS Health in a research note on Thursday, October 25th. They issued a “peer perform” rating for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. CVS Health presently has a consensus rating of “Buy” and an average target price of $90.04.
CVS traded down $0.51 during trading on Wednesday, reaching $79.33. 6,568,352 shares of the stock were exchanged, compared to its average volume of 7,515,497. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.94 and a current ratio of 2.44. The company has a market cap of $81.42 billion, a price-to-earnings ratio of 13.45, a PEG ratio of 1.07 and a beta of 0.98. CVS Health has a 1 year low of $60.14 and a 1 year high of $83.88.
CVS Health (NYSE:CVS) last posted its earnings results on Tuesday, November 6th. The pharmacy operator reported $1.73 EPS for the quarter, topping the Zacks’ consensus estimate of $1.71 by $0.02. CVS Health had a return on equity of 18.69% and a net margin of 1.65%. The company had revenue of $47.27 billion for the quarter, compared to the consensus estimate of $47.22 billion. During the same period in the previous year, the business earned $1.50 earnings per share. CVS Health’s quarterly revenue was up 2.4% compared to the same quarter last year. On average, analysts predict that CVS Health will post 7.03 EPS for the current fiscal year.
In other CVS Health news, EVP Troyen A. Brennan sold 14,229 shares of the stock in a transaction that occurred on Wednesday, November 14th. The stock was sold at an average price of $82.00, for a total transaction of $1,166,778.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Kevin Hourican sold 8,564 shares of the stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $75.00, for a total value of $642,300.00. Following the transaction, the executive vice president now directly owns 12,135 shares in the company, valued at approximately $910,125. The disclosure for this sale can be found here. Insiders sold 57,638 shares of company stock valued at $4,558,875 in the last three months. 0.53% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the business. Camarda Financial Advisors LLC acquired a new stake in CVS Health in the 2nd quarter valued at approximately $102,000. Canton Hathaway LLC acquired a new position in shares of CVS Health during the 3rd quarter valued at $126,000. Kiley Juergens Wealth Management LLC acquired a new position in shares of CVS Health during the 2nd quarter valued at $103,000. MCF Advisors LLC increased its position in shares of CVS Health by 284.1% during the 3rd quarter. MCF Advisors LLC now owns 1,713 shares of the pharmacy operator’s stock valued at $135,000 after purchasing an additional 1,267 shares during the period. Finally, Legacy Advisors LLC increased its position in shares of CVS Health by 7,100.0% during the 2nd quarter. Legacy Advisors LLC now owns 1,800 shares of the pharmacy operator’s stock valued at $116,000 after purchasing an additional 1,775 shares during the period. 82.55% of the stock is currently owned by institutional investors.
About CVS Health
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Further Reading: How dollar cost averaging works